Avantor Q2 Feels The Impact From Bioprocessing Shortfalls, Customer Headwinds, Continued Margin Pressure
1. AVTR's Q2 2025 EPS was 24 cents, below expectations of 25 cents. 2. Sales reached $1.68 billion, slightly matching consensus but down 1% year-over-year. 3. Net income fell to $64.7 million, down from $92.9 million last year. 4. Laboratory Solutions sales decreased by 3%, with organic sales down 1%. 5. Goldman Sachs downgraded AVTR amid a significant 60% decline since 2021.